Merck shares slide as investors weigh kidney-cancer trial setback ahead of a near-term FDA decision

Merck shares slide as investors weigh kidney-cancer trial setback ahead of a near-term FDA decision  Quiver Quantitative

Summary aggregated from Quiver Quantitative's public RSS feed. The full reporting belongs to Quiver Quantitative — please read it on their site.